227 related articles for article (PubMed ID: 9521220)
1. Multiple sclerosis: what have we learned from magnetic resonance imaging studies?
Khoury SJ; Weiner HL
Arch Intern Med; 1998 Mar; 158(6):565-73. PubMed ID: 9521220
[TBL] [Abstract][Full Text] [Related]
2. Multiple sclerosis and interferon beta-1b, past, present and future.
Horowski R
Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
[No Abstract] [Full Text] [Related]
3. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
Frohman EM; Racke M; van Den Noort S
Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
[No Abstract] [Full Text] [Related]
4. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.
Richert ND; Ostuni JL; Bash CN; Leist TP; McFarland HF; Frank JA
Mult Scler; 2001 Feb; 7(1):49-58. PubMed ID: 11321194
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials.
Frank JA; Bash C; Stone L; Petrella J; Maloni H; McFarland H
Acad Radiol; 1996 Aug; 3 Suppl 2():S173-5. PubMed ID: 8796554
[No Abstract] [Full Text] [Related]
6. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.
Beck RW; Chandler DL; Cole SR; Simon JH; Jacobs LD; Kinkel RP; Selhorst JB; Rose JW; Cooper JA; Rice G; Murray TJ; Sandrock AW
Ann Neurol; 2002 Apr; 51(4):481-90. PubMed ID: 11921054
[TBL] [Abstract][Full Text] [Related]
7. Newer long-term treatments for multiple sclerosis.
Pryse-Phillips W
Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
[No Abstract] [Full Text] [Related]
8. Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis.
Paty DW; Li DK; Oger JJ; Kastrukoff L; Koopmans R; Tanton E; Zhao GJ
Ann Neurol; 1994; 36 Suppl():S95-6. PubMed ID: 8017896
[TBL] [Abstract][Full Text] [Related]
9. Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
O'Connor P;
Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786
[No Abstract] [Full Text] [Related]
10. The treatment of multiple sclerosis: current and future.
Polman CH; Hartung HP
Curr Opin Neurol; 1995 Jun; 8(3):200-9. PubMed ID: 7551119
[TBL] [Abstract][Full Text] [Related]
11. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
Rice G
Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
[No Abstract] [Full Text] [Related]
12. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
[TBL] [Abstract][Full Text] [Related]
13. [Cognitive disturbances and attempts of their correction in multiple sclerosis].
Shmidt TE
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(9):54-6. PubMed ID: 16252387
[No Abstract] [Full Text] [Related]
14. [Magnetic resonance angiography in multiple sclerosis].
Pati DV; Vorobeĭchik G
Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(12):53-7. PubMed ID: 10629934
[No Abstract] [Full Text] [Related]
15. Multiple sclerosis therapy. A practical guide.
van Oosten BW; Truyen L; Barkhof F; Polman CH
Drugs; 1995 Feb; 49(2):200-12. PubMed ID: 7729328
[TBL] [Abstract][Full Text] [Related]
16. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
[TBL] [Abstract][Full Text] [Related]
17. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
Frese A; Bethke F; Lüdemann P; Stögbauer F
Neurology; 1999 Nov; 53(8):1892-3. PubMed ID: 10563657
[No Abstract] [Full Text] [Related]
18. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
[TBL] [Abstract][Full Text] [Related]
19. The curious incident of disability in multiple sclerosis trials.
Coles A
Lancet Neurol; 2006 Nov; 5(11):899-900. PubMed ID: 17052654
[No Abstract] [Full Text] [Related]
20. Interferon beta-1a in primary progressive multiple sclerosis.
Leary SM; Thompson AJ
J Neurol Sci; 2003 Feb; 206(2):215-6. PubMed ID: 12559514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
